Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ultomiris (ravulizumab-cwvz)
Pharma
AZ touts Ultomiris results in post-transplant complication trial
Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug to make its mark.
Fraiser Kansteiner
Jun 16, 2025 10:32am
AZ’s Alexion creates interactive storybook for kids with aHUS
Feb 12, 2025 12:00pm
Argenx's Vyvgart holds its own against AZ's rare disease duo
Jul 25, 2024 3:16pm
AstraZeneca's rare disease add-on therapy Voydeya scores FDA nod
Apr 1, 2024 11:48am
FDA expands AZ's Ultomiris to NMOSD after prior rejection
Mar 25, 2024 10:31am
Roche's answer to AstraZeneca PNH drugs nabs China nod
Feb 8, 2024 11:02am
